{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:37:24Z","timestamp":1793763444126,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.antiviral.2014.01.001","type":"journal-article","created":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T02:05:39Z","timestamp":1389405939000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Predictive value of interferon-gamma inducible protein 10kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients"],"prefix":"10.1016","volume":"103","author":[{"given":"Yadong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.01.001_b0145","doi-asserted-by":"crossref","first-page":"CR698","DOI":"10.12659\/MSM.883595","article-title":"Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver","volume":"18","author":"Bae","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.antiviral.2014.01.001_b0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI40594","article-title":"Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV","volume":"121","author":"Casrouge","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2014.01.001_b0015","doi-asserted-by":"crossref","first-page":"e36984","DOI":"10.1371\/journal.pone.0036984","article-title":"Persistent hepatitis B viral replication in a FVB\/N mouse model: impact of host and viral factors","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.01.001_b0020","first-page":"1948","article-title":"Expression of IL-8, IP-10 and its mRNA in serum and PBMC of the patients with primary hepatic carcinoma","volume":"37","author":"Cui","year":"2010","journal-title":"Mod. Prev. Med."},{"key":"10.1016\/j.antiviral.2014.01.001_b0025","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1365-2036.2011.04635.x","article-title":"IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C","volume":"33","author":"Fattovich","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2014.01.001_b0030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.001_b0035","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","article-title":"Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues","volume":"16","author":"Jaroszewicz","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2014.01.001_b0040","first-page":"422","article-title":"T helper cells in patients with chronic hepatitis B virus infection","volume":"115","author":"Jiang","year":"2002","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.antiviral.2014.01.001_b0150","doi-asserted-by":"crossref","first-page":"e17232","DOI":"10.1371\/journal.pone.0017232","article-title":"Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms","volume":"6","author":"Lagging","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.01.001_b0155","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.24221","article-title":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir","volume":"53","author":"Lee","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.01.001_b0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepat. Int."},{"key":"10.1016\/j.antiviral.2014.01.001_b0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2893.1998.00098.x","article-title":"Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B","volume":"5","author":"Lok","year":"1998","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2014.01.001_b0065","first-page":"244","article-title":"Detection and clinical significance of serum interferon-inducible protein-10 and interferon-\u03b3 in patients with severe hepatitis B","volume":"26","author":"Luo","year":"2008","journal-title":"Chin. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.01.001_b0070","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2011.10.020","article-title":"High serum IL-21 levels after 12weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B","volume":"56","author":"Ma","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.001_b0080","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-09-1052","article-title":"Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer\/T-cell lymphoma cells","volume":"15","author":"Moriai","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2014.01.001_b0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2362.2011.02623.x","article-title":"IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV\u2013HCV-coinfected patients","volume":"42","author":"Payer","year":"2012","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2014.01.001_b0090","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1177\/135965350801300815","article-title":"IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV\u2013HCV coinfection","volume":"13","author":"Reiberger","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2014.01.001_b0095","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.01.001_b0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/507307","article-title":"Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection","volume":"194","author":"Romero","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.01.001_b0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-008-9106-x","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)","volume":"3","author":"Sarin","year":"2009","journal-title":"Hepat. Int."},{"key":"10.1016\/j.antiviral.2014.01.001_b0165","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2013.01.029","article-title":"Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B","volume":"58","author":"Sonneveld","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.001_b0115","first-page":"280","article-title":"Relationship between the expression of IP-10 and IP-10 mRNA in peripheral blood and HBV DNA level in patients with cirrhosis","volume":"9","author":"Wang","year":"2010","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.antiviral.2014.01.001_b0120","first-page":"45","article-title":"Expression of CXC chemokine IP-10 in patients with chronic hepatitis B","volume":"7","author":"Wang","year":"2008","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.antiviral.2014.01.001_b0125","unstructured":"WHO, July 2012. Hepatitis B, Fact sheet No. 204."},{"issue":"165\u2013172","key":"10.1016\/j.antiviral.2014.01.001_b0130","first-page":"e161","article-title":"Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion","volume":"138","author":"Wu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.001_b0135","first-page":"250","article-title":"CXCR3 and IP 10 expression in patients with chronic hepatitis B and their correlation with degree of liver inflammation and hepatic fibrosis","volume":"34","author":"Yang","year":"2012","journal-title":"Acta Academiae Medicinae Militaris Tertiae"},{"key":"10.1016\/j.antiviral.2014.01.001_b0140","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jir424","article-title":"CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C","volume":"204","author":"Zeremski","year":"2011","journal-title":"J. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T19:04:14Z","timestamp":1688929454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":27,"alternative-id":["S0166354214000023"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of interferon-gamma inducible protein 10kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2014 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}